Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0HMWS | ISIN: SE0000652216 | Ticker-Symbol: N/A
1-Jahres-Chart  (nicht börsennotiert)
ICA GRUPPEN AB Chart 1 Jahr
GlobeNewswire (Europe)
213 Leser
Artikel bewerten:
(1)

ICA Gruppen AB: ICA Gruppen's report for the first quarter 2024

Finanznachrichten News

Press release

Solna

2024-04-25

More customers choose ICA and Apotek Hjärtat which drives volumes and improves earnings

  • Consolidated net sales increased by 7.4% to SEK 37,150 million compared with 2023 (SEK 34,605 million) for the first quarter and operating profit rose to SEK 1,490 million (SEK 1,293 million)
  • The Group's improved earnings were affected by positive calendar effects such as the leap day and an early Easter as well as the fact that we recognised major non-recurring costs in the corresponding quarter in the previous year.
  • The quarter was characterised by strong customer flows which led to increased market shares for ICA Sweden. Customers are also buying more items each time they shop which taken overall contrbuted to improved earnings for ICA Sweden.
  • The operating margin for ICA Sweden, which sells goods to the ICA retailers, was 3.6% compared with 2.7% in the corresponding quarter last year. At the same time, food price increases normalised during the quarter.
  • More customers are also choosing to shop at Apotek Hjärtat which further strengthened its leading position as Sweden's largest pharmacy. Apotek Hjärtat's sales increased to SEK 5,153 million (4,503)
  • Rimi Baltic also took market shares but had a weaker operating profit than in the corresponding quarter last year
  • The Group made a bond issue of SEK 2 billion

Comments by ICA Gruppen's CEO, Nina Jönsson:

"The year has started well with significantly lower food price inflation and a food price initiative now being rolled out in the stores. It is gratifying to see that customers are returning to ICA at the same time as the number of products in baskets is rising again - and this can of course be seen in stronger earnings, largely driven by these higher volume. Price remains important to our customers and it is therefore more relevant than ever that we invest to improve prices over time. Already last year, several ICA stores, especially the larger ones and the Rimi stores, started investments in reduced prices and March saw the rollout in Sweden of the price initiative in Sweden announced earlier. This will take place in stages and provide lasting lower price levels - and an improved price experience - for key everyday products. We can already see greater momentum with higher customer flows and there are indications that the ICA stores are now showing the strongest performance in the market. An excellent start on which to build."

For more information
ICA Gruppen press service, telephone number: +46 (0)10 422 52 52, e-mail: press@ica.se

Frans Benson, Head of Investor Relations, telephone number: +46 (0)8 561 500 57

icagruppen.se

ICA Gruppen AB (publ) is one of the leading retail companies in the Nordic countries with a focus on food and health. The Group includes ICA Sweden and Rimi Baltic, which mainly conduct grocery retail, ICA Real Estate, which owns and manages properties, ICA Bank, which offers financial services, ICA Insurance, and Apotek Hjärtat, which conducts pharmacy business. ICA Gruppen had sales of approximately SEK 148 billion in 2023. For more information visit icagruppen.se.

This information is such that ICA Gruppen AB is obligated to make public in accordance with the Swedish Securities Market Act. The information was submitted for publication by the contact person above at 07.00 CET on Thursday, 25 April 2024.


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.